Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences expanded its Caris AI Insights portfolio with a new AI signature designed to ...
RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing ...
Researchers built an open tool to handle complex genome sequencing data, offering automated quality control, improved variant ...
This is a preview. Log in through your library . Abstract The molecular mechanism of plant polyploid stress resistance has been a hot topic in biological research. In this study, Populus diploids and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results